Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption
European Journal of Pharmaceutics and Biopharmaceutics · 2023-04 · 185 · 165-176
DOI: 10.1016/j.ejpb.2023.02.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023-04. Verfasst von Dengning Xia und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. Electronic address: xiadn@mail.sysu.…. Hauptthemen laut MEDLINE: Nanoparticles, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
Oral chemotherapy can improve the life quality of patients; however, the therapeutic effects are limited by low bioavailability and rapid in vivo elimination of anticancer drugs. Here, we developed a regorafenib (REG)-loaded self-assembled lipid-based nanocarrier (SALN) to improve oral absorption and anti-colorectal cancer efficacy of REG through lymphatic absorption. SALN was prepared with lipid-based excipients to utilize lipid transport in the enterocytes and enhance lymphatic absorption of the drug in the gastrointestinal tract. The particle size of SALN was 106 ± 10 nm. SALNs were internalized by the intestinal epithelium via the clathrin-mediated endocytosis, and then transported across the epithelium via the chylomicron secretion pathway, resulting in a 3.76-fold increase in drug epithelial permeability (Papp) compared to the solid dispersion (SD). After oral administration to rats, SALNs were transported by the endoplasmic reticulum, Golgi apparatus, and secretory vesicles of enterocytes and were found in the lamina propria of intestinal villi, abdominal mesenteric lymph, and plasma. The oral bioavailability of SALN was 65.9-fold and 1.70-fold greater than that of the coarse powder suspension and SD, respectively, and was highly dependent on the lymphatic route of absorption. Notably, SALN prolonged the elimination half-life of the drug (9.34 ± 2.51 h) compared to the solid dispersion (3.51 ± 0.46 h), increased the biodistribution of REG in the tumor and gastrointestinal (GI) tract, decreased biodistribution in the liver, and showed better therapeutic efficacy than the solid dispersion in colorectal tumor-bearing mice. These results demonstrated that SALN is promising for the treatment of colorectal cancer via lymphatic transport and has potential for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. Electronic address: xiadn@mail.sysu.edu.cn.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; Nano Science and Technology Institute, University of Science and Technology of China, Suzhou 215123, China.
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
Zitieren
APA
Xia, D., Hu, C., & Hou, Y. (2023). Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption. European Journal of Pharmaceutics and Biopharmaceutics, 185, 165-176. https://doi.org/10.1016/j.ejpb.2023.02.016
Vancouver
Xia D, Hu C, Hou Y. Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption. European Journal of Pharmaceutics and Biopharmaceutics. 2023;185:165-176. doi:10.1016/j.ejpb.2023.02.016
BibTeX
@article{Xia2023,
author = {Xia, Dengning and Hu, Cunde and Hou, Yulin},
title = {Regorafenib loaded self-assembled lipid-based nanocarrier for colorectal cancer treatment via lymphatic absorption},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2023},
volume = {185},
pages = {165--176},
doi = {10.1016/j.ejpb.2023.02.016}
}
EUVIMED